Clinical trial
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
NCT00491699 · Symphony Evolution, Inc., Industry · Terminated
Key facts
| NCT number | NCT00491699 |
|---|---|
| Title | Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer |
| Official title | A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC) |
| Lead sponsor | Symphony Evolution, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | XL999 |
| Enrollment | 2 |
| Start date | Aug 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Jun 26, 2007 |
| Last update posted | Feb 19, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: